大黄蟅虫丸与拉米夫定联合治疗慢性乙型肝炎活动性肝硬化的临床疗效观察

Clinical therapeutic effect of da huang zhe chong wan and lamivudine on the active cirrhosis of chronic hepatitis C.

目的探讨大黄蟅虫丸和拉米夫定治疗慢性乙型肝炎活动性肝硬化的临床疗效。方法随机选择86例活动性肝硬化患者,治疗组46例,大黄蟅虫丸1丸,1日2次,6个月为1疗程;拉米夫定0.1g,1日1次,疗程1年,产生应答者继续服用药物半年。各组在性别、年龄、病程及疾病轻重等方面皆具可比性。观察治疗前后肝功能及1、3、6、12个月的HBV-DNA变化。结果大黄蟅虫丸和拉米夫定治疗组与对照组比较,肝功能、HBV-DNA的阴转率增加,经统计学处理差异有显著性(P<0.05)。结论大黄蟅虫丸和拉米夫定治疗活动性肝硬化有明显的临床疗效。

Objective To investigate the clinical therapeutic effect of da huang zhe chong wan and lamivudine on the active hepatocirrhosis of chronic hepatitis. Methods 86 patients with active hepatocirrhosis received da huang zhe chong wan and lamivudine（ da huang zhe chong wan lwan daily for 6 months,lamivudine O. 1 g daily for 1 year）. The liver function before and after da huang zhe chong wan and lamivudine ad-ministration and HBV-DNA at 1,3,6,and 12 months after matrine and laxnivudine treatment were detected. Results The negative conversion rate of HBV-DNA and liver function was increased in treatment group comparing with the control group,with statistical significance （ P 〈 0.05 ）. Condusion da huang zhe chong wan and lamivudine show an obvious effect in the treatment of active hepatoeirrhosis.